SkylineDx debuted its new MMprofiler™ with SKY92 campaign this year during the European Hematology Association conference in Denmark. MMprofiler with SKY92 enables physicians to quickly and confidently identify high-risk multiple myeloma patients.
Genomic testing continues to become more actionable and mainstream in equipping physicians to provide personalized care for their patients. A personalized approach is very much needed in the treatment of multiple myeloma where a significant percentage of the 124,000 patients can be classified as high-risk for disease progression.
MMprofiler™ with SKY92 is not available in the United States.